---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-274670"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2021-09-16T23:59:59+00:00"
generated_at: "2026-06-29T03:20:52.065827+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities

## Summary
- Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.
- Avitide expected to contribute ~$10M revenue in 2022 and be accretive to adjusted EPS in 2023.
- Transaction strengthens Repligen's affinity ligand discovery platform for gene therapy and other modalities.
- Deal expected to close in Q3 2021; funded with cash on hand ($734M at June 30, 2021).

## SEC filing metadata
- accession: 0001193125-21-274670
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2021-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/0001193125-21-274670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312521274670/d217967d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-274670
- JSON: https://secwatch.observer/filing/0001193125-21-274670.json
- Plain text: https://secwatch.observer/filing/0001193125-21-274670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.